Vaccination Plus Ontak in Patients With Metastatic Melanoma

Stopped early · Phase 2

Conditions studied: Melanoma

In brief

The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.

Key facts

Study ID
NCT00515528
Run by
University of Chicago
People needed
17
Starts
2007-04-23
Expected to finish
2016-03-01
Last updated by the study team
2021-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.